Retatrutide in the UK

What retatrutide is

Retatrutide is a synthetic peptide: a manufactured molecule with a defined amino-acid sequence, distinct from the naturally occurring hormones it resembles. It acts as an agonist at three receptors — the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon receptor. An agonist binds a receptor and activates it, initiating the same class of signalling as the receptor’s native ligand.

Triple agonist refers to that coverage of three receptors, and to nothing else. It does not describe a three-part construction: GLP-1, GIP and glucagon are closely related members of one peptide family with conserved segments in common, so a single engineered sequence can be tolerated at all three receptors. Retatrutide is a single continuous chain rather than three linked fragments. Dual agonists cover two of the three receptors — commonly GLP-1 and GIP, the pairing in tirzepatide, though GLP-1 and glucagon pairings also exist. Relative potency at each receptor differs between molecules in this class and is not implied by either label.

Retatrutide is an investigational compound: it holds no UK marketing authorisation, and no licensed medicine in the UK contains it. Peptide Global supplies it as an in-vitro research compound for laboratory use by qualified researchers, in the pre-mixed pen format described below. It is not supplied for administration to humans or animals.

Retatrutide’s regulatory status in the UK

Retatrutide holds no marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), and the MHRA products register carries no entry for it, which any reader can confirm directly. Its originator’s clinical development programme remained ongoing as at August 2026.

What research-use-only status excludes

Research-use-only material sits outside the medicines framework altogether. There is no MHRA oversight of its manufacture, no Qualified Person batch release, no pharmacopoeial monograph against which it could be assessed, and no pharmacovigilance reporting route. No part of this supply is regulated as a medicine, and none of it should be read as equivalent to a pharmacy supply chain.

What Peptide Global is not

Peptide Global is not a pharmacy and not a registered healthcare provider. It does not supply medicines and does not give medical or clinical advice. The enquiries it can answer concern specification, storage and cold-chain handling, and dispatch.

All material listed on this site, the Retatrutide Pen 40 mg included, is supplied for laboratory research use only. It is not for human or veterinary use, and not for any diagnostic or therapeutic application.

Responsibility and legal questions

Purchasers are responsible for their own compliance with applicable law and with the requirements of their institution or ethics committee. Nothing on this page is legal advice, and nothing here states what any reader may or may not do. Readers with questions about their own position should put them to their legal advisers or their institution’s compliance office.

Why retatrutide is not available from a UK pharmacy

A UK pharmacy dispenses against a prescription, and the medicine it dispenses ordinarily holds a marketing authorisation valid in the United Kingdom: a specific formulation, strength and presentation, assessed and licensed for supply. A second route covers unlicensed medicines, or specials, which a prescriber may order to meet the special clinical needs of an individual patient; a special must still be manufactured or imported by the holder of the relevant MHRA licence, so it reaches the patient through a licensed supply chain.

Retatrutide holds no UK marketing authorisation, and as a compound still in clinical development it is supplied to trial investigators rather than placed on the market as a finished medicine that a licensed manufacturer or importer could source. Several UK pharmacies state on their own websites that they cannot supply it.

Peptide Global is not a pharmacy and does not present itself as one. It supplies research-grade material to laboratories and research professionals: an order involves no prescription, no clinical assessment and no pharmacist, and nothing supplied is intended for human or veterinary use. The Retatrutide Pen 40 mg is laboratory reagent held in a dial-dosing cartridge, supplied for research use only.

What “research use only” actually means

The phrase is used literally. Material supplied for research use only is intended for in-vitro laboratory investigation. It is not formulated, tested or authorised for administration to humans or animals, and it is not a food, a supplement, a cosmetic or a medical device. It falls outside all of those categories, which is why it carries none of the labelling, usage instructions or patient information that any of them would require.

The designation also describes the basis of supply. Orders are accepted on the understanding that the purchaser is a qualified researcher, or is buying for a laboratory, institution or comparable organisation, and that the material will be handled as a laboratory reagent. That understanding forms part of the transaction rather than a note appended to it.

What the designation does not do is convert anything. A compound with no UK marketing authorisation does not acquire one because a supplier labels it for research. The wording describes intended use and terms of sale; it has no bearing on the regulatory status of the substance, and it is not a disclaimer that alters that status. Read as a workaround, it has been misread.

Retatrutide is supplied on that basis here. The cartridge specifications and cold-chain requirements set out on this page describe a laboratory item, not anything intended for use in people.

Pre-mixed pens and lyophilised vials: the trade-off

Research peptides are supplied in one of two formats, and neither is unambiguously the better choice. Everything in the pre-mixed peptide pen range uses the first of them. A lyophilised vial holds freeze-dried peptide as a solid cake. It must be reconstituted with bacteriostatic water before anything can be drawn from it, and that step is where variability enters:

• the volume of diluent added, which sets the final concentration
• how the vial is mixed, and whether the solid dissolves fully
• how long the vial spends at room temperature before it returns to cold storage
• the accuracy of the syringe used to measure the diluent and each later draw

None of this is difficult, but it is done by hand and repeated whenever a fresh vial is opened. Two people reconstituting identical vials can arrive at materially different concentrations.

Against that, the vial holds an advantage no pen can match. Held under the same conditions, a sealed lyophilised vial keeps its condition longer than the same peptide already dissolved. The reason is physical, not commercial: the routes by which peptides degrade in solution (hydrolysis, deamidation, aggregation) need water, and a dry solid offers very little of it. Where material is bought to be held rather than used soon, that differential decides the format.

A pre-mixed pen removes the reconstitution step and its variability. Volume per click is fixed by the pen’s mechanics, and concentration is fixed at manufacture, so a given click count dispenses the same quantity of peptide every time. On the Retatrutide Pen 40 mg the dial is graduated at 15 clicks per 2 mg, and a 3 ml cartridge gives 20 such increments. Nothing is diluted on site and nothing is measured by eye.

The cost is the point above: the solution is made up at manufacture, so the useful window is shorter and cold-chain handling (2–8 °C, protected from light, never frozen) matters more than for a sealed powder.

	Pre-mixed pen	Lyophilised vial
Preparation before use	None. Supplied in solution.	Reconstitution with bacteriostatic water.
Concentration set by	Manufacture, once.	Whoever reconstitutes it, each time.
Repeatability	A click count corresponds to a fixed mass.	Depends on diluent volume, mixing and transfer losses.
Long-term storage	Shorter useful window — already in solution.	Longer while sealed and dry.
Cold chain	Matters throughout.	Matters less while sealed.
Best suited to	Consistent handling and prompt use.	Holding stock over time.

Stated plainly: a pen suits work where handling consistency and prompt use matter; a lyophilised vial suits long-term storage of stock. Both formats are supplied for laboratory research use only.

Retatrutide pen cartridge strength

Cartridge strength is the total mass of retatrutide sealed inside the cartridge. It is not a per-click figure, and on its own it does not describe the solution: concentration is strength divided by fill volume, so a strength figure only becomes meaningful once the volume it sits in is known. Two cartridges quoting different strengths are not comparable until both fill volumes are stated, and the same strength in a smaller fill volume is the more concentrated solution.

The compound is identical whatever the strength; what differs is concentration. Mass and volume are consequently separate quantities — the mass contained in any measured volume follows from the concentration of that specific cartridge, not from the strength printed on it.

Peptide Global supplies a single strength: 40 mg of retatrutide in a 3 ml cartridge, 13.33 mg/ml. The dial is graduated at 15 clicks per 2 mg, so a full cartridge covers 20 increments of 2 mg.

Graduation is a property of the pen rather than of the compound. Clicks are a device unit and not a unit of mass: a clicks-per-mg figure is a specification of the particular pen it is quoted for, it cannot be derived from cartridge strength alone, and where a supplier does not state it the mass per increment of that pen is not determinable.

How dial graduation works on a pre-mixed pen

A pre-mixed pen fixes two quantities: the concentration in the sealed cartridge, set at manufacture, and the distance the dial advances the plunger per click. Clicks therefore map to volume, and concentration converts volume to mass.

Worked example: Retatrutide Pen 40 mg

Quantity	Retatrutide Pen 40 mg
Cartridge strength	40 mg
Fill volume	3 ml
Concentration	13.33 mg/ml
Dial graduation	15 clicks = 2 mg
One click displaces	0.01 ml (10 µl), about 0.13 mg
Increments per cartridge	20 nominal — see the caveat below
Clicks per cartridge	300 nominal

The 40 mg pre-mixed cartridge holds 40 mg of retatrutide in 3 ml, a concentration of 13.33 mg/ml. It is graduated at 15 clicks per 2 mg, so one click advances the plunger 0.01 ml (10 microlitres), about 0.13 mg at that concentration. Fifteen clicks displace 0.15 ml, which is 2 mg; a full cartridge counts 20 such increments, or 300 clicks in total. These are device figures: what the mechanism displaces, not what should be dispensed.

Where the arithmetic stops

With reconstituted material, whoever mixes it creates the concentration: vial overfill, diluent volume and transfer losses shift the mass per unit volume, so one syringe marking need not mean the same mass twice. A sealed cartridge settles that figure once, so a click count means the same mass anywhere in the cartridge. The count of 20 is the softer figure: twenty increments at 0.15 ml is 3.00 ml exactly, the nominal fill, with nothing left for dead volume at the outlet, losses on first advancing the mechanism, or drive tolerance. A full 20 should not be assumed.

What the graduation depends on

• Temperature: solution straight from 2–8 °C is more viscous and leaves the cartridge more slowly than at room temperature; equilibrating first removes that variable.
• Agitation: the solution is homogeneous as supplied, so shaking mixes nothing and only adds air.
• Orientation: it sets where the air space sits relative to the outlet, and so whether an increment displaces solution or air.
• An unsealed outlet: an open fluid path lets solution seep out and air enter, changing the volume remaining and later increments.
• Storage: 2–8 °C, protected from light, not frozen — the conditions the stated concentration assumes.

Sourcing retatrutide in the UK for research

Peptide Global holds retatrutide stock in the United Kingdom, so dispatch does not wait on an import. Clearance happens before an order is placed rather than after it, and the interval a purchaser plans around is a domestic delivery time.

Cartridges are held at 2–8 °C, protected from light and never frozen, and packed with coolant for transit. Orders placed before 2pm UK time on a working day are dispatched the same day. Outer packaging is plain. The contents require refrigeration on arrival, so a delivery is best timed against cold storage at the receiving laboratory rather than left to sit unattended.

Payment is by open banking or direct bank transfer. Supply is to laboratories and research professionals; the material is for research use only.

Retatrutide is stocked in one format, the Retatrutide Pen 40 mg: 40 mg in a sealed 3 ml pre-mixed cartridge, dial-graduated at 15 clicks per 2 mg, so a full cartridge dispenses 20 increments of 2 mg. Lyophilised vials are not supplied; every compound listed is a pre-mixed pen. A workflow that depends on weighing powder, selecting its own diluent, or preparing a concentration other than the one already in the cartridge is not served by this format.

Common questions

Is the retatrutide pen available in the UK?

Yes, as a research material rather than as a medicine. What differs between suppliers is whether stock is held in the UK or brought in once an order is placed, which is worth confirming rather than inferring from a listing. Peptide Global holds the Retatrutide Pen 40 mg as UK stock.

What is a reta pen?

“Reta pen” is informal shorthand for retatrutide supplied in a click-dial pen device rather than a lyophilised vial. The cartridge holds the compound already in solution, and the dial sets the volume dispensed at each increment. The term describes a format, not a grade or specification, so what it means depends on the cartridge fill.

How many clicks is 2 mg on a retatrutide pen?

On the Retatrutide Pen 40 mg the dial is graduated at 15 clicks per 2 mg. That figure is a property of the device and of the concentration in that cartridge, so it does not transfer to pens filled differently. Check the graduation stated for the pen in hand rather than assuming a common value.

How many increments does a 40 mg cartridge dispense?

Twenty, at 2 mg each, across the 3 ml fill. That is a nominal figure: a small residual volume stays in the cartridge and device, so the count actually deliverable can be lower.

Does a pre-mixed pen need reconstituting?

No. The cartridge is filled with stabilised solution and sealed, so there is no bacteriostatic water, no mixing step and no transfer between containers. Removing that step also removes the variability it introduces, at the cost of a fixed concentration that cannot be changed.

Is retatrutide a licensed medicine in the UK?

No. Retatrutide holds no UK marketing authorisation and is not an approved medicinal product; it is an investigational triple agonist at the GLP-1, GIP and glucagon receptors. UK marketing authorisations are granted by the MHRA, and the absence of one is a matter of regulatory record. Nothing here is advice on what a reader may lawfully do; anyone needing that should take their own regulatory advice.

How should a retatrutide pen be stored?

At 2–8 °C, protected from light, and not frozen. Orders leave cold-packed in plain outer packaging, so the pen should go into refrigerated storage on arrival. Cold-packing covers transit only; those conditions apply for as long as the cartridge is held.

Is retatrutide for human use?

No. It is supplied for laboratory research use only and is not for human or veterinary administration, consumption or any in-vivo application. That basis applies to every order and cannot be varied by agreement.

Related formats and compounds

Retatrutide is one of thirteen compounds supplied in this same pre-mixed pen format. Those closest to it by receptor class, and the wider range:

• Retatrutide Pen 40 mg — the pen this page describes: 40 mg in a sealed 3 ml cartridge, graduated at 15 clicks per 2 mg.
• Tirzepatide Pen 60 mg — a dual agonist, acting at the GLP-1 and GIP receptors but not the glucagon receptor, in the same cartridge format.
• Cagrilintide Pen 10 mg — an amylin analogue, acting at the amylin and calcitonin receptors rather than the incretin receptors.
• Pre-mixed peptide pens — all thirteen pens, with how the cartridge format and dial graduation work.
• Single peptide pens — one compound per cartridge.
• Peptide blend pens — two or more compounds combined at manufacture in a fixed ratio.

Storage requirements are the same across the range and are set out under storage and handling. Dispatch, cold-packing and delivery terms are on the shipping and delivery page.

Research use only